5-(4-溴苯基)噻吩-2-甲醛 | 38401-70-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(4-溴苯基)噻吩-2-甲醛
• 英文名称: 5-(4-bromophenyl)thiophene-2-carbaldehyde
• CAS: 38401-70-6
• 化学式: C₁₁H₇BrOS
• mdl: MFCD00829312
• 分子量: 267.146
• InChiKey: HKRFAVKXDXDKBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-(4-溴苯基)噻吩-2-甲醛 在 六甲基磷酰三胺 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 硫酸 、 silver(l) oxide 作用下， 以 四氢呋喃 、 乙醚 、 水 、 甲苯 为溶剂， 反应 7.0h， 生成 2-(4-Bromophenyl)-5-(chloromethyl)thiophene
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents

  摘要：

  5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)- thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate acid (5d), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.08.009
• 作为产物：
  描述：

  4'-溴-4-氯苯丁酮 在 硫酸 、 三氯氧磷 作用下， 以 甲醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成 5-(4-溴苯基)噻吩-2-甲醛
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents

  摘要：

  5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)- thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate acid (5d), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.08.009

文献信息

• [EN] 4 ( 1H) -PYRIDINONE DERIVATIVES AND THEIR USE AS ANTIMALARIA AGENTS<br/>[FR] DÉRIVÉS DE 4(1H)-PYRIDINONE ET LEUR UTILISATION COMME AGENTS ANTIPALUDIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2010081904A1

  公开（公告）日：2010-07-22

  4-pyridone (4-pyridinone) derivatives of Formula (I) and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.

  4-吡啶酮（4-吡啶酮）的衍生物，其化学式为（I），以及其药用可接受的衍生物，其制备方法，药物配方以及它们在化疗特定寄生虫感染如疟疾中的应用。
• [EN] COMPOUNDS, PREPARATIONS AND USES THEREOF<br/>[FR] COMPOSÉS, LEURS PRÉPARATIONS ET LEURS UTILISATIONS
  申请人：PETER MACCALLUM CANCER INST

  公开号：WO2011075784A1

  公开（公告）日：2011-06-30

  The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity.

  本发明提供了式（I）的新化合物，包括这些化合物的药物组合物以及使用这些化合物作为抑制穿孔素活性的药剂或药物，用于治疗患有与不良穿孔素活性相关的疾病或紊乱、或处于患有风险或易感染某种疾病或紊乱的受试者的方法。
• Synthesis and evaluation of thiophene-based guanylhydrazones (iminoguanidines) efficient against panel of voriconazole-resistant fungal isolates
  作者：Vladimir Ajdačić、Lidija Senerovic、Marija Vranić、Marina Pekmezovic、Valentina Arsic-Arsnijevic、Aleksandar Veselinovic、Jovana Veselinovic、Bogdan A. Šolaja、Jasmina Nikodinovic-Runic、Igor M. Opsenica

  DOI：10.1016/j.bmc.2016.01.058

  日期：2016.3

  inhibited C. albicans yeast to hyphal transition, essential for its biofilm formation, while 11 and 18 were able to disperse preformed Candida biofilms. All guanylhydrazones showed the equal potential to interact with genomic DNA of C. albicans in vitro, thus indicating a possible mechanism of their action, as well as possible mechanism of observed cytotoxic effects. Tested compounds did not have significant

  使用简单的两步程序以高收率合成了一系列新的基于噻吩的胍基hy​​dr（亚氨基胍）。与临床使用的药物伏立康唑相比，针对多种医学上重要的真菌菌株（包括酵母，霉菌和皮肤真菌）对化合物的抗真菌活性进行了评估。还使用人肺成纤维细胞系和溶血测定法测定了化合物的细胞毒性。所有鸟嘌呤showed均显示出对多种临床上重要的念珠菌，烟曲霉，尖孢镰刀菌，犬小孢子菌和毛癣菌的广谱活性。，在某些情况下与伏立康唑的活性相当或更好。更重要的是，化合物10，11，13，14，18和21表现出对耐伏立康唑，优异的活性白色念珠菌CA5具有非常低的最低抑菌浓度（MIC）值<2微克毫升-1。苯环上带有溴的衍生物14是最有效的化合物，MIC的范围为0.25至6.25μgmL -1。然而，双脒腙18在治疗指数值方面显示出更好的选择性。对斑马鱼的体内胚胎毒性（斑马鱼）显示的改进的毒性谱11，14和18相比，该伏立康唑。大多数胍hydr
• Oxo-Imidazolyl Compounds
  申请人：Bearss David J.

  公开号：US20090298900A1

  公开（公告）日：2009-12-03

  Compounds represented by Formula I and II, or pharmaceutically acceptable salts thereof: inhibit bacterial 2-epimerase and are useful anti-infective agents.

  由化学式I和II代表的化合物，或其药用可接受的盐：抑制细菌2-表皮酶，是有用的抗感染剂。
• 一种氟硼荧有机小分子二聚体及其制备方法 和在有机光伏器件中的应用
  申请人：中国科学院化学研究所

  公开号：CN106810572B

  公开（公告）日：2019-04-09

  本发明涉及一种通式I化合物及其制备方法以及其在有机光伏领域的应用。本发明还涉及含有通式I化合物的有机太阳能电池及其制备方法。所述通式I化合物是通过8号位桥联的BODIPY小分子二聚体结构，其在可见光区具有很宽的光谱覆盖(300—800nm)，能够更有效、充分的利用太阳光。并且，式I化合物中的结晶性桥联单元，能够利于分子在与受体材料的混合态条件下的有序堆积，显著提高太阳能电池器件的电流，从而提高材料的效率。